Padmanabhan Mannangatti

Padmanabhan Mannangatti

Auto-generated profile, based on publicly available information

Padmanabhan Mannangatti

Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
PBPraveen Bhoopathi
Praveen Bhoopathi
PMPadmanabhan Mannangatti
Padmanabhan Mannangatti
LELuni Emdad
Luni Emdad
SDSwadesh K. Das
Swadesh K. Das
Paul FisherPaul Fisher
Paul Fisher

29 June 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
APAnjan K. Pradhan
Anjan K. Pradhan
JMJinkal Modi
Jinkal Modi
SMSantanu Maji
Santanu Maji
AKAmit Kumar
Amit Kumar
PBPraveen Bhoopathi
Praveen Bhoopathi
Paul FisherPaul Fisher
Paul Fisher
Genome-wide gene expression analysis and animal modeling indicate that melanoma differentiation associated gene-9 (mda-9, Syntenin, Syndecan binding protein, referred to as MDA-9/Syntenin) positively regulates melanoma metastasis. The MDA-9/Syntenin protein contains two tandem PDZ domains serving as a nexus for interactions with multiple proteins that initiate transcription of metastasis-associated genes. Although targeting either PDZ domain abrogates signaling and prometastatic phenotypes, the integrity of both domains is critical for full biological function. Fragment-based drug discovery and NMR identified PDZ1i, an inhibitor of the PDZ1 domain that effectively blocks cancer invasion in vitro and in vivo in multiple experimental animal models. To maximize disruption of MDA-9/Syntenin signaling, an inhibitor has now been developed that simultaneously binds and blocks activity of both PDZ domains. PDZ1i was joined to the second PDZ binding peptide (TNYYFV) with a PEG linker, resulting in PDZ1i/2i (IVMT-Rx-3) that engages both PDZ domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression, culminating in repression of melanoma metastasis. The in vivo antimetastatic properties of IVMT-Rx-3 are enhanced when combined with an immune-checkpoint inhibitor. Collectively, our results support the feasibility of engineering MDA-9 dual-PDZ inhibitors with enhanced antimetastatic activities and applications of IVMT-Rx-3 for developing novel therapeutic strategies effectively targeting melanoma and in principle, a broad spectrum of human cancers that also overexpress MDA-9/Syntenin.

2 October 2023
Verified
Other
Open access
APAnjan K. Pradhan
Anjan K. Pradhan
JMJinkal Modi
Jinkal Modi
SMSantanu Maji
Santanu Maji
AKAmit Kumar
Amit Kumar
PBPraveen Bhoopathi
Praveen Bhoopathi
Paul FisherPaul Fisher
Paul Fisher
Genome-wide gene expression analysis and animal modeling indicate that melanoma differentiation associated gene-9 (mda-9, Syntenin, Syndecan binding protein, referred to as MDA-9/Syntenin) positively regulates melanoma metastasis. The MDA-9/Syntenin protein contains two tandem PDZ domains serving as a nexus for interactions with multiple proteins that initiate transcription of metastasis-associated genes. Although targeting either PDZ domain abrogates signaling and prometastatic phenotypes, the integrity of both domains is critical for full biological function. Fragment-based drug discovery and NMR identified PDZ1i, an inhibitor of the PDZ1 domain that effectively blocks cancer invasion in vitro and in vivo in multiple experimental animal models. To maximize disruption of MDA-9/Syntenin signaling, an inhibitor has now been developed that simultaneously binds and blocks activity of both PDZ domains. PDZ1i was joined to the second PDZ binding peptide (TNYYFV) with a PEG linker, resulting in PDZ1i/2i (IVMT-Rx-3) that engages both PDZ domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression, culminating in repression of melanoma metastasis. The in vivo antimetastatic properties of IVMT-Rx-3 are enhanced when combined with an immune-checkpoint inhibitor. Collectively, our results support the feasibility of engineering MDA-9 dual-PDZ inhibitors with enhanced antimetastatic activities and applications of IVMT-Rx-3 for developing novel therapeutic strategies effectively targeting melanoma and in principle, a broad spectrum of human cancers that also overexpress MDA-9/Syntenin.


27 November 2025
Verified
Other
Open access
PDF file
APAnjan K. Pradhan
Anjan K. Pradhan
JMJinkal Modi
Jinkal Modi
SMSantanu Maji
Santanu Maji
AKAmit Kumar
Amit Kumar
PBPraveen Bhoopathi
Praveen Bhoopathi
Paul FisherPaul Fisher
Paul Fisher
IVMT-Rx-3 inhibited invasion in murine melanoma cells

27 November 2025
Verified
Other
Open access
PDF file
APAnjan K. Pradhan
Anjan K. Pradhan
JMJinkal Modi
Jinkal Modi
SMSantanu Maji
Santanu Maji
AKAmit Kumar
Amit Kumar
PBPraveen Bhoopathi
Praveen Bhoopathi
Paul FisherPaul Fisher
Paul Fisher
MDA-9 downregulation impacted the invasiveness of patient derived melanoma cells